Australia's most trusted
source of pharma news
Wednesday, 13 May 2026
Posted 13 May 2026 AM
Daiichi Sankyo has unveiled a five-year business plan with the goal of becoming one of the world’s top five oncology companies.
Unveiled on Monday, alongside its 2025 results, the antibody-drug conjugate (ADC) leader outlined how it intends become one of the top five oncology players by 2035.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.